Search alternatives:
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
wt decrease » we decrease (Expand Search), _ decrease (Expand Search), awd decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
6241
-
6242
Overview of pathway differences observed between FLT3-ITD and FLT3-WT AML samples across the two studies.
Published 2010“…White coloring and non-bold lines indicate decreased pathway activity. Dotted line from FLT3L to p-Stat5 in FLT3-WT samples indicates connectivity in a subset of patients. …”
-
6243
-
6244
[Ca<sup>2+</sup>] dynamics comparison between WT network and blocking an individual NFA-sensitive channel.
Published 2014“…J) <i>CaKC</i> on scenario 2 (activating <i>CaKC</i>), the decrease in peak, average and amplitude values. The central column (B, E, H and K) is the comparison between amplitude and mean of the dynamics between the WT curve and those with altered channels. …”
-
6245
-
6246
-
6247
3D-Printed Diamond–Titanium Composite: A Hybrid Material for Implant Engineering
Published 2019“…The addition of diamond to the biomaterial results in a 30% decrease in the water contact angle, making the scaffolds more hydrophilic and improving cellular adhesion and proliferation.…”
-
6248
-
6249
-
6250
Procedure related data, LBNP, LBPP and hypoxia.
Published 2023“…Decreasing levels of LBNP were applied in 5-minute steps until subjects reached presyncope. …”
-
6251
Individual biometric data of patients.
Published 2023“…Decreasing levels of LBNP were applied in 5-minute steps until subjects reached presyncope. …”
-
6252
The NK1-receptor antagonist ezlopitant significantly decreases voluntary intake of non-caloric saccharin solution.
Published 2013“…<p>Ezlopitant (5 and 10 mg/kg) significantly decreased consumption of the non-caloric 0.2% saccharin solution compared to vehicle. …”
-
6253
-
6254
-
6255
-
6256
The NK1-receptor antagonist ezlopitant significantly and selectively decreases voluntary intake of both sucrose and ethanol.
Published 2013“…<p>Ezlopitant decreased consumption of 5% sucrose (<b>A</b>), whereas only the highest dose of ezlopitant (10 mg/kg) decreased consumption of 20% ethanol (<b>B</b>). …”
-
6257
-
6258
-
6259
-
6260